News

Article

ICYMI: Highlights From AAD 2024

Author(s):

Key Takeaways

  • Ruxolitinib cream for vitiligo showed 60% of patients maintained benefits post-treatment, with potential for skin repigmentation upon reinitiation.
  • JNJ-2113 demonstrated significant efficacy in plaque psoriasis, achieving primary end point in a phase 2b trial.
SHOW MORE

The 2024 American Academy of Dermatology conference was held in San Diego, California March 8 to 11.

The 2024 American Academy of Dermatology (AAD) conference took place in San Diego, California, from March 8 to 11, and our top content from the meeting covered research presented on treatments for vitiligo, plaque psoriasis, mental health and stigma, atopic dermatitis (AD), and hidradenitis suppurativa. Experts also spoke to their research and promising long-term findings from several studies.

This is our top AAD 2024 coverage, and you can also catch up on all of our conference coverage on our dedicated AAD page.

5. Dr John Harris Outlines the Outcomes of Stopping Treatment With Ruxolitinib Cream for Vitiligo

In this interview, John Harris, MD, PhD, FAAD, director of the Vitiligo Clinic and Research Center at UMass Chan Medical School, discussed results from the withdrawal arm of the TRuE-V extension study of ruxolitinib cream in vitiligo. He explained that approximately 40% of patients relapse within 1 year of stopping treatment, and although that can be interpreted as disappointing, it also means 60% continue to see benefit from the topical Janus kinase inhibitor. Also, those who stopped treatment with ruxolitinib and reinitiated were able to achieve skin repigmentation, he explained.

Watch this interview.

4. Dr Laura Ferris Discusses Safety, Efficacy of JNJ-2113 in Patients With Plaque Psoriasis

For this interview, Laura Ferris, MD, PhD, professor of dermatology, University of Pittsburgh, stopped by to discuss findings on the investigative agent JNJ-2113, which was being evaluated for use in patients with moderate to severe plaque psoriasis. Findings from the double blind, placebo controlled, multidose phase 2b FRONTIER 2 clinical trial (NCT05364554) showed that 76.2% of patients achieved Psoriasis Area and Severity Index score of 75% or greater skin improvement, which was the primary end point. Additional efficacy end points she and her team investigated at the time were improvement in scalp psoriasis, patients signs and symptoms of psoriasis, and safety.

Watch this interview.

Vitiligo image | Image Credit: © LIGHTFIELD STUDIOS-stock.adobe.com

Our top 2024 AAD content encompassed research presented on treatments for vitiligo, plaque psoriasis, atopic dermatitis, and hidradenitis suppurativa. | Image Credit: © LIGHTFIELD STUDIOS-stock.adobe.com

3. Patients With Vitiligo Suffer Heightened Stigma, Mental Health Risks

Patients who have the chronic autoimmune disorder vitiligo experience loss of pigmentation on patches of skin. The research covered in this conference session explored the stigma and mental health consequences of vitiligo, showing there remains a great need for health care for these patients that combines aspects of medical and psychological management. Patients living with vitiligo have higher odds of experiencing anxiety, depression, and obsessive-compulsive disorder, which can have a significant impact on their quality of life, and there remains a great need for strategies that help improve the mental well-being of this population.

Read this article.

2. Dupilumab Considered Safe, Effective Treatment for Adolescent, Adult Patients With AD

This poster wrap of 2 independent analyses that incorporated data from the ongoing GLOBOSTAD trial (NCT03992417) showed dupilumab to be safe and effective over the long term. Patients were enrolled in GLOBOSTAD if they were 12 years or older and had moderate to severe AD. Patient and physician reports showed rapid improvements in skin lesions, itch, sleep, and overall quality of life, following patients evaluations at baseline, and then again at 3, 6, and 12 months after initiating dupilumab.

Read this article.

1. Late-Breaking Abstracts Highlight Promising Therapies in AD, Hidradenitis Suppurativa

In our top article from AAD 2024, promising late-breaking research was presented on treatments shown effective against AD and hidradenitis suppurativa, which encompassed topical therapies and systemic treatments, namely biologics and Janus kinase inhibitors. Lawrence F. Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children’s Hospital in San Diego; Jill S. Waibel, MD, FAAD, subsection chief of dermatology at Baptist Hospital; and Jonathan I. Silverberg, MD, PhD, MPH, FAAD, director of clinical research at The George Washington University School of Medicine and Health Sciences, presented their analyses on roflumilast cream, lebrikizumab, and nemolizumab, respectively, for AD. In the same session, Martina J. Porter, MD, dermatologist at Beth Israel Deaconess Medical Center, and Brian Kirby, professor at St. Vincent’s Private Hospital in Dublin, Ireland, presented findings on ruxolitinib cream and sonelokimab, respectively, for hidradenitis suppurativa.

Read this article.

Related Videos
Picture of San Diego skyline with words ASH Annual Meeting 2024 and health icons overlaid on the bottom
Screenshot of an interview with Amir Ali, PharmD, BCOP
Mansi Shah, MD, assistant professor, Rutgers Cancer Institute of New Jersey
 Alvaro Alencar, MD, associate professor of clinical medicine, chief medical officer, University of Miami Sylvester Comprehensive Cancer Center
Dr Cesar Davila-Chapa
Screenshot of an interview with Nadine Barrett, PhD
Milind Desai, MD
Masanori Aikawa, MD
Neil Goldfarb, GPBCH
Mabel Mardones, MD.
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo